How is PE-22-28 administered?
This describes how PE-22-28 is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous or intranasal, on a daily schedule, generally over 2-4 weeks. Specific dosing is individual and beyond general information, and human evidence for PE-22-28 is limited.
Administration at a glance (reference data)
- Route: Subcutaneous or intranasal
- Schedule: Daily
- Cycle length: 2-4 weeks
- Half-life: Short (~hours)
References
- PE-22-28: a novel peptide for fast-acting antidepressant treatment — Mazella J et al., PLoS Biol, 2010
- Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity — Djillani A et al., Frontiers in Pharmacology, 2017
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on PE-22-28
Last updated 2026-06-15.